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Abstract
Remote damage is a secondary phenomenon that usually occurs after a primary brain damage in regions that are distant, yet
functionally connected, and that is critical for determining the outcomes of several CNS pathologies, including traumatic brain
and spinal cord injuries. The understanding of remote damage-associated mechanisms has been mostly achieved in several
models of focal brain injury such as the hemicerebellectomy (HCb) experimental paradigm, which helped to identify the
involvement of many key players, such as inflammation, oxidative stress, apoptosis and autophagy. Currently, few interventions
have been shown to successfully limit the progression of secondary damage events and there is still an unmet need for new
therapeutic options. Given the emergence of the novel concept of resolution of inflammation, mediated by the newly identified
ω3-derived specialized pro-resolving lipid mediators, such as resolvins, we reported a reduced ability of HCb-injured animals to
produce resolvin D1 (RvD1) and an increased expression of its target receptor ALX/FPR2 in remote brain regions. The in vivo
administration of RvD1 promoted functional recovery and neuroprotection by reducing the activation of Iba-1+ microglia and
GFAP+ astrocytes as well as by impairing inflammatory-induced neuronal cell death in remote regions. These effects were
counteracted by intracerebroventricular neutralization of ALX/FPR2, whose activation by RvD1 also down-regulatedmiR-146b-
and miR-219a-1-dependent inflammatory markers. In conclusion, we propose that innovative therapies based on RvD1-ALX/
FPR2 axis could be exploited to curtail remote damage and enable neuroprotective effects after acute focal brain damage.
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Abbreviations
GFAP Glial fibrillary acidic protein
HCb Hemicerebellectomy
Rv Resolvin
RvD1 Resolvin D1
SPM Specialized pro-resolving mediators
Introduction
A primary brain damage of the central nervous system (CNS),
as in traumatic brain and spinal cord injuries, often results in
severe functional impairment that is highly dependent on the
secondary damage, a cascade of reactive changes occurring in
response to the primary insult. Major components of second-
ary injury are inflammatory responses, including activation of
resident glial cells and generation of pro-inflammatory
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mediators [1]. These secondary events amplify the effect of
the primary injury and continue in the weeks following the
initial insult also in distant areas that are partially affected or
unaffected by the primary damage [2, 3] and are critical for the
overall clinical profile in many acute CNS pathologies.
This last delayed phenomenon, termed Bremote damage^ [4],
can last for days, weeks, or months and is sustained by many
factors, including etiology, alterations of mitochondrial dynam-
ics, autophagy, glial inflammation, and oxidative stress [4–8].
These events are mediated by the up-regulation of genes
that play a key role in both the damage and repair of injured
neural tissue and whose critical balance between their pro- and
anti-survival effects determines injury progression and
outcome.
Among the remote damage-associated mechanisms, in-
flammation is central to death/survival choices [3]. Indeed,
inflammation is fundamentally a protective cellular response
aimed at removing injurious stimuli and initiating the healing
process, but when unresolved, it can become chronic,
resulting in organ dysfunction [9, 10] and causing further in-
flammation and damage also in distally remote regions [6].
Although knowledge of such remote damage-associated
mechanisms has considerably improved, there is still an unmet
need for new therapeutic options. Hence, the identification of
mediators limiting the inflammation and/or involved in the
resolution of inflammation is of growing interest and it may
provide novel targets for these conditions.
In this context, previously unrecognized metabolites,
termed specialized pro-resolving lipid mediators (SPMs), tem-
porally and spatially synthesized from ω-3 essential fatty
acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid
[DHA]), were recently identified as potent mediators that con-
trol the magnitude and extent of inflammatory events by acti-
vating local resolution programs [11, 12]. Among these,
DHA-derived D-series resolvins have received considerable
attention in recent years due to their ability to reduce inflam-
mation in different disease models such as kidney injury and
cardiovascular and autoimmune disorders [13]. Indeed, recent
studies have reported that dietary supplementation of DHA or
in vivo administration of DHA-derived metabolites are neu-
roprotective, attenuate inflammatory responses, and promote
functional recovery in several murine models of brain injury
[14, 15], including spinal cord injury (as reviewed in [16]).
In this study, we examined the alterations in the Bresolution
of inflammation^ pathway, in particular of two major D-series
resolvins, i.e., resolvin D1 (RvD1) and resolvin D2 (RvD2)
and the pharmacological effects of resolvins in an in vivo
model of focal CNS lesion, focusing on remote changes that
are induced by hemicerebellectomy (HCb). HCb is a well-
known and highly reproducible model that is used to study
remote cell death [8]. In this model, neuronal degeneration is
induced by target deprivation and axonal damage of contra-
lateral neurons of the inferior olive (IO) and pontine nuclei
(Pn) [8]. Herein, we found that the pro-resolution pathway of
RvD1 is altered in HCb-lesioned rats and that the pharmaco-
logical treatment of RvD1 promotes functional recovery and
protects HCb-lesioned rats against remote neuronal cell death
and neuroinflammation.
Materials and Methods
Animals and HCb Lesion
Experiments were performed using 80 adult (70–80 days)
male Wistar rats (200–220 g) group-housed in standard cages
and maintained under a 12 h light–dark cycle in an air-
conditioned facility. The Italian Ministry of Health approved
the experimental protocol (authorization no. DM444-2015
PR) in agreement with the guidelines of the European
Communities Council Directive 2010/63/EU for the care and
use of laboratory animals. All efforts were made to minimize
the number of animals used and their suffering. For surgical
procedures, the rats were anesthetized by intraperitoneal (i.p.)
injections of xylazine (Rompun, 10 mg/kg) and tiletamine and
zolepam (Zoletil 100, 25 mg/kg) in a stereotaxic apparatus.
The skin of the skull was incised, the occipital bone was
drilled and removed, the dura mater incised to expose the
cerebellum, and hemicerebellectomy (HCb) was induced by
removal of the right cerebellar hemisphere, as described pre-
viously [4, 5, 17]. For the control (CTRL) group, surgery was
interrupted after the dura lesion was made, and after suturing,
the animals were returned to their cages. The different exper-
imental groups are listed in Table 1.
Drugs and Treatments
For the in vivo studies, the following pro-resolving lipid me-
diator was used: resolvin D1 (7S,8R,17S-trihydroxy-
4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid, Cayman
Chemicals; 0.4 μg /kg, i.p.). Further, the following neutraliz-
ing antibody was used: ALX/FPR2 (50 μg/kg, i.c.v. on day 3).
All the animals that were treated with RvD1 received one i.p.
of RvD1 after HCb lesion and then again every 2 days (at days
3, 5, and 7), whereas a single intracerebroventricular injection
(i.c.v.) of anti-ALX/FPR2 at day 3. Treatments in the different
experimental groups are listed in Table 1 and antibodies used
in Supplementary Table 2.
Detection of Resolvins
CSF from CTRL and HCb animals was kept at − 80 °C. The
levels of RvD1 and RvD2were measured through quantitative
competitive Cayman’s ELISA kits, based on the competition
between free RvD1/RvD2 Tracers for a limited number of
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RvD1/RvD2-specific rabbit antiserum binding sites, accord-
ing to standard procedure (assay sensitivity of 15 pg/ml).
Neurological Evaluation
The Neurologic Severity Score (NSS) was used to evaluate
neurological conditions in rats. NSS is a composite of motor,
sensory, reflex, and balance tests in which, for each test, one
point is awarded for the inability to perform or for the lack of a
tested reflex, and zero points are awarded for success. The
NSS was evaluated at 24 and 72 h and 5 and 7 days after
damage by an investigator who was blind to the experimental
groups, as reported [4, 5, 17].
Histology and Immunohistochemistry
Anesthetized animals were perfused transcardially with 4%
paraformaldehyde, brains removed immediately, post-fixed
in the same paraformaldehyde solution, and transferred to
30% sucrose solution at 4 °C. A series of sections (30-μm-
thick) involving pontine nuclei (Pn) were processed for im-
munohistochemical studies. Following incubation with a so-
lution of primary antibodies, the sections were incubated for
2 h at room temperature with specific secondary antibodies.
Sections were examined under a confocal laser scanning mi-
croscope (Zeiss LSM700) and analyzed through qualitatively
and quantitatively and also by means of Sholl analysis as
reported [18] and detailed below.
Qualitative and Quantitative Analyses
Qualitative and quantitative observations were limited to the
Pn of the experimental side that was projecting to the lesioned
hemicerebellum. Using the Stereo Investigator System
(MicroBrightField Europe e.K.), an optical fractionator, ste-
reological design, was applied to obtain unbiased estimates of
total Nissl-stained cells. A stack of MAC 5000 controller
modules (Ludl Electronic Products Ltd) was configured to
interface an Olympus BX 50 microscope with a motorized
stage and a HV-C20 Hitachi color digital camera with a
Pentium II PC workstation. A three-dimensional optical dis-
sector counting probe (x, y, z dimension of 30 × 30 × 10 μm,
respectively) was applied. Five sections for each specimen
were analyzed, and Pn was outlined using the × 5 objective,
while the × 100 oil immersion objective was used for marking
the neuronal cells. The total Pn cell number was estimated
according to the formula
N ¼ ΣQ 1=ssf  1=asf  1=tsf
where ΣQ represents the total number of neurons counted in
all optically sampled fields of the Pn, ssf is the section sam-
pling fraction, asf is the area sampling fraction, and tsf is the
thickness sampling fraction. All quantitative analyses were
conducted blinded to the animal’s experimental group
identity.
Sholl Analysis
Microglia in the Pn were imaged using an optical microscope
(DMLB, Leica) equippedwith a motorized stage and a camera
connected to software (Neurolucida 7.5, MicroBright-Field)
that allowed a quantitative 3D analysis of the entire compart-
ment. Only microglia that displayed intact processes
unobscured by background labeling or other cells were includ-
ed in reconstructions. Five cells per animals per group were
randomly selected for a total of 60 cells included for analysis.
The cell body area, perimeter, number of intersection, number
of nodes (branch points), and total length of all processes were
measured. To account for changes in the cell’s complexity in
relation to distance from the cell soma, Sholl analyses were
performed for each microglial cell. Concentric circles (radii)
were spaced 10 μm apart, originating from the soma. The
number of branch points (nodes), processes that intersected
the radii, and process length were measured as a function of
the distance from the cell soma for each radius [18].
Table 1 Lesion and treatments in
the different experimental groups Groups Number Treatment
Ctrl (CTRL) 16 /
Ctrl + resolvin D1 (RvD1) 14 Resolvin D1 0.4 μg/kg, i.p. on days 0, 3, 5, and 7
HCb 1 day 3 /
HCb 3 days 3 /
HCb 5 days 3 /
HCb 7 days 16 /
HCb 7 days + resolvin D1 (HCb + RvD1) 16 Resolvin D1 0.4 μg/kg, i.p. on days 0, 3, 5, and 7
HCb 7 days + resolvin D1 +ALX/FPR2
(HCb + RvD1 + anti-ALX/FPR2)
9 Resolvin D1 0.4 μg/kg, i.p. on days 0, 3, 5, and 7 and
ALX/FPR2 0.75 ng/kg, i.c.v. on day 3
CTRL control,HCb hemicerebellectomy, RvD1 resolvin D1, ALX/FPR2 annexin lipoxin/N-formyl peptide recep-
tor 2, i.p. intraperitoneal, i.c.v. introcerebroventricular
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Western Blotting
Total proteins were extracted in RIPA buffer whereas cytosol-
ic proteins in hypotonic buffer. Samples were subjected to
SDS–PAGE, transferred to nitrocellulose filters, and
immunoreacted with specific primary antibodies and then
with the appropriate horseradish peroxidase-conjugated sec-
ondary antibodies. Immunoreactive bands were detected by
CDiGit Chemiluminescent Western Blot Scanner (LI-COR
Biosciences), as reported [19].
Real-Time qPCR of MicroRNA and Target Genes
TriReagent (Invitrogen, Thermo Scientific, CA, USA) was
used to isolate total RNA from rat brain remote regions.
MicroRNA analysis was carried out in triplicate with the
TaqMan® Individual microRNA assays (Applied
Biosystems) according to the manufacturer’s instructions.
Amplification signal detection was carried out using the
Applied Biosystems ViiA 7 Real-Time PCR System.
MicroRNAs that displayed threshold cycles (Ct) > 33 were
excluded from the analysis. Results were analyzed using the
2−ΔCt relative quantification method using the small non-
coding RNA 4.5S RNA(H) as reference housekeeping
microRNA and normalized to β-actin as endogenous control,
as reported [20].
Bioinformatics Analysis
MicroRNA.org [21] (http://www.microrna.org/microrna/
home.do) database was queried for microRNA target genes,
where microRNA-target interactions were predicted with
miRanda 3.3a and scores were calculated with mirSVR (< 0.
1) [22].
Statistical Analysis
Statistical analysis was performed through GraphPad Prism
6.0 (GraphPad software for Science, San Diego, CA). All data
were expressed as means ± SEM. Differences between groups
were compared using Student’s t test (two groups) or one-way
or two-way ANOVA (multiple groups) followed by a
Bonferroni post hoc test. The criterion for statistical signifi-
cance was P < 0.05 or less.
Results
The Pro-Resolution Pathway of RvD1 Is Altered in HCb-
Lesioned Rats Since several evidences reported extensive
neuroinflammatory and neurodegenerative changes upon
HCb lesion at remote regions (Fig. 1a), we first wondered
whether injured animals exhibited possible alterations in the
Bresolution of inflammation^ pathway, by assessing the levels
of two major D-series resolvins, i.e., resolvin D1 (RvD1) and
resolvin D2 (RvD2), and the expression of their target recep-
tors. Analyzing the CSF of lesioned (HCb) and control
(CTRL) animals after 7 days of injury, we observed a reduction
in RvD1 and RvD2 levels, particularly significant for RvD1
(Fig. 1b). By contrast, no variation in the levels of both pro-
resolving lipid mediators uponHCb injury was observed in the
periphery, namely in plasma (Fig. S1A). Thus, we next inves-
tigated the ability of HCb animals to respond to RvD1 and to
activate pro-resolution programs in remote brain regions (i.e.,
pontine nuclei, Pn) by measuring the expression of its target
receptor ALX/FRP2 also after 7 days of injury. Western blot-
ting analysis revealed a significant up-regulation of ALX/
FPR2 during HCb (Fig. 1c), which was also corroborated by
immunohistochemical and confocal analysis, showing a mark-
edly stronger staining of this receptor in HCb animals com-
pared to CTRL brains. Interestingly, double immunofluores-
cence of ALX/FPR2 and GFAP, a marker of astrocytes, dem-
onstrated that ALX/FPR2 was strongly induced exclusively in
reactive astrocytes (Fig. 1d) whereas double-labeling of ALX/
FPR2 with Iba1, a microglial marker or with NeuN, a neuronal
marker, showed that neither microglial (Fig. S2) nor neuronal
(Fig. S2B) cells did express ALX/FPR2 in Pn.
RvD1 Promotes Functional Recovery and Protects HCb-
Lesioned Rats against Remote Neuronal Cell Death and
Neuroinflammation Given the alteration of RvD1 pathway
during HCb, in terms of its production and expression of its
key molecular targets, we next tested the pharmacological
actions of RvD1 in HCb animals (Table 1). Upon HCb, rats
were evaluated for neurological conditions as measured by
Neurological Severity Score (NSS) 24 h after lesion and then
every 2 days in presence or absence of i.p. injection of RvD1
(0.4 μg/kg at days 0, 3, 5, and 7) (Fig. 2a). We found that
systemic treatment with RvD1 (HCb + RvD1) promoted func-
tional recovery as early as 3 days after lesion compared to
untreated animals (HCb) (Fig. 2b). This beneficial effect on
neurological symptoms was maintained also at days 5 and 7,
whereby HCb animals receiving RvD1 treatment significantly
showed constantly reduced NSS scores. Furthermore, against
a marked reduction in neuronal cells, paralleled by an increase
in cytochrome-c (Cyt-c) release during HCb, animals receiv-
ing RvD1 displayed a neuroprotective profile, inasmuch as
RvD1 protected Pn neurons from HCb-induced degeneration
by increasing neuronal survival (Fig. 2c) and by reducing Cyt-
c expression and release (Fig. 2c, d). These neuroprotective
effects were also coupled with a marked reduction of HCb-
induced reactive astrocytes and microglia. Accordingly, we
observed a significant decrease in the number of GFAP-
positive astrocytes and of Iba1-positive microglial cells in
RvD1-treated animals as shown both by immunohistochemical
(Fig. 3a) and western blotting (Fig. 3b) analyses. Intriguingly,
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when attentively observing the morphology of Iba-1+ microglial
cells, we noticed that RvD1 treatment was associated with mor-
phological changes. Thus, we performed Sholl analysis and
found that at 7 days after HCb microglial cells of axotomized
Pn displayed a higher degree of complexity and ramification
compared to CTRL, presenting a larger cell body (Fig. 3c, gray
arrowhead) and thicker and more branched processes (Fig. 3c,
white arrowhead), as well as longer ramifications, increased
number of intersections and nodes, larger ramification perimeter,
and area (Fig. S4A-E). Conversely, treatment with RvD1 showed
a de-ramified morphology compared to HCb, showing signifi-
cantly thinner and less ramified processes (Fig. 3c). Similarly,
microglia process length, intersections, and nodes, as well as total
perimeter and area, were significantly reduced in RvD1-treated
animals (Fig. S4A-E).
RvD1 Regulates the Expression of Pro-Resolving MicroRNAs
and of their Target Genes in HCb-Lesioned Rats Since select-
ed microRNA (miR-21, miR-142, miR-146b, miR-208,
miR-219, and miR-203) profiles have been shown to be
temporally regulated by RvD1 and ALX/FPR2 in acute
self-limited inflammation in mice [23], we asked whether
they could also be involved in the neuroprotective and
anti-inflammatory effects exerted by RvD1 in the HCb
model. Thus, we investigated the expression of
microRNA in the remote regions of HCb and HCb +
RvD1-treated animals, finding that all the candidates ex-
amined were detectable, except miR-208. Among the dif-
ferent candidates, only miR-146b and miR-219a-1-3p
were significantly up-regulated in HCb + RvD1-treated
animals compared to HCb animals (Fig. 4b). Next, we
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Fig. 1 The pro-resolving pathway of RvD1 is altered in HCb. a
Schematic of the hemicerebellectomy (HCb) model. Due to the crossed
input–output organization of the cerebellar connections, unilateral lesion
of a cerebellar hemisphere induces axonal lesions and subsequent
degeneration of the contralateral (experimental side) pontine nuclei
(Pn), with sparing of Pn on the ipsilateral side (control side). b
Quantification of RvD1 and RvD2 levels in cerebrospinal fluid (CSF)
of CTRL and HCb animals by ELISA. *P < 0.01 by Student’s t test. c
Western blotting bands and densitometry of ALX/FPR2 receptors in Pn.
**P < 0.01 by Student’s t test. d Immunofluorescence staining of ALX/
FPR2 receptor. Double-labeled and merged confocal images of GFAP
(green) plus DAPI counterstaining (blue) and ALX/FPR2 receptor (red)
in Pn of CTRL and HCb animals. The last panel represents the graphic
representation (scatter plot) of the correlation coefficient of Pearson
(PCC) for quantifying the co-localization between the ALX/FPR2 and
GFAP in CTRL and HCb animals (PCC = 0.56 in HCb vs PCC = 0.00 in
CTRL). Higher PCC values correspond to a strong co-localization (Scale
bar = 50 μm). Results are mean ± SEM or representative of N = 6 rats
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sought to investigate some of the gene targets that could
be regulated by miR-146b and miR-219a-1-3p. To do so,
the microRNA.org database was queried to search for
putative mRNA targets regulated by the microRNAs of
interest (Fig. 4a). Among these, we focused on those
genes with functions in immune systems, namely, TLR4
under the regulation of both miR-219-1-3p and miR-146b
as well as CD200 under the regulation of miR-219-1-3p.
In addition, we also investigated NF-kB and IL6R,
known to be targeted by miR-146b according to the lit-
erature [23, 24]. As shown in Fig. 4c, RvD1 treatment
was associated with a significant reduction in IL6R and
TLR4. These findings suggest that RvD1-induced protec-
tive effects in HCb might be associated with modulation
of specific microRNA-regulated inflammatory genes
(Supplementary Table 3).
RvD1 Neuroprotective Effects Are Mediated by ALX/FPR2
Since ALX/FPR2 was significantly up-regulated in Pn dur-
ing HCb (Fig. 1c–e), we hypothesized that it could play a
critical role in mediating RvD1-induced protective effects.
Thus, we investigated the effects of inhibiting ALX/FPR2
downstream pathways. In order to choose the appropriate
time-point at which pharmacologically antagonizing RvD1
receptor, we first assessed its time-course expression during
HCb lesion. The western blotting analysis of ALX/FPR2
revealed a bell-shaped expression, with a significant up-
regulation at 3 and 5 days after HCb lesion and a down-
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Fig. 2 RvD1 promotes functional recovery and protects from neuronal
cell death. HCb rats were left untreated or treated with RvD1 at days 0, 3,
5, and 7 (0.4 μg /kg, i.p.). a Treatment protocol employed in the study. b
Time course of neurological recovery (NSS). **P < 0.01 and
***P < 0.001 (CTRL vs HCb) and #P < 0.05 (HCb vs HCb + RvD1) by
two-way ANOVA followed by Bonferroni’s post hoc test. c
Immunofluorescence staining and merged confocal images of NeuN-
positive neurons (green) and cytochrome-c (cyt-c, red) in Pn of CTRL,
HCb, and HCb + RvD1 animals (scale bar = 25 μm). ***P < 0.001 vs
CTRL and ###P < 0.001 vs HCb. dWestern blotting bands and densitom-
etry of cyt-c. ***P < 0.001 vs CTRL, ###P < 0.001 vs HCb by one-way
ANOVA followed by Bonferroni’s post hoc test. Results are mean ± SEM
for N = 6 rats
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regulation at day 7 (Fig. S3). Thus, we decided to neutralize
ALX/FPR2 receptor at day 3, being the first time-point at
which its protein level was significantly evident in
axotomized Pn. Intracerebroventricular administration of
neutralizing ALX/FPR2 antibody at day 3 in presence of
systemic treatment with RvD1 significantly prevented the
functional recovery observed in HCb animals treated with
RvD1, when compared to HCb (Fig. 5a). Furthermore, it
completely abolished the effects of RvD1 in reducing the
density of Iba1 and GFAP immunoreactive cells (Fig. 5b).
Interestingly, the RvD1-induced changes in the morphology
of activated microglia during HCb were also counteracted
upon neutralization of ALX/FPR2, with microglial cells
returning back to a more ramified and hypertrophic mor-
phology (Figs. 5c and S4A-E). Additionally, to test whether
ALX/FPR2 was involved in mediating the RvD1-induced
neuroprotective effects via modulation of miR-146b and
miR-219a-1-3p, we also evaluated whether its neutraliza-
tion could modulate the microRNA-regulated circuits pre-
viously shown to be affected by RvD1. In particular,
blocking ALX/FPR2 not only significantly down-
regulated both microRNAs (Fig. 5d) but also up-regulated
IL6R and TLR4 (Fig. 5e, f), suggesting that RvD1 exerts its
neuroprotective effects via ALX/FPR2 receptor and its
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Fig. 3 RvD1 reduces microglia and astrocyte responses. a
Immunofluorescence staining of microglia and astrocytes upon RvD1
treatment. Double-labeled and merged confocal images of Iba-1 (red)
plus DAPI counterstaining (blue) (upper panel) and GFAP (green) plus
DAPI counterstaining (blue) (lower panel) in Pn of CTRL, HCb, and
HCb + RvD1 animals (scale bar = 50 μm). ***P < 0.001 vs CTRL;
###P < 0.001 vs HCb. b Western blotting bands and densitometry of
Iba-1 and GFAP. ***P < 0.001 vs CTRL. ###P < 0.001 vs HCb by one-
way ANOVA fol lowed by Bonfer roni ’s post hoc tes t . c
Immunofluorescence staining of microglia upon treatment with RvD1.
Single labeled images of Iba-1 in Pn of CTRL, HCb, and HCb + RvD1
groups (scale bar = 25 μm) and representative images of 3D-
reconstructed microglia phenotypes. Results are mean ± SEM or repre-
sentative of N = 6 rats
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regulated microRNAs that mainly impact on the neuroin-
flammation induced by HCb injury (Fig. 5e).
Discussion
In the present work, we reported for the first time that RvD1, a
specialized pro-resolving lipid mediator (SPM) derived from
DHA, promotes functional recovery and halts glial activation
and neuronal death in an in vivo model of remote damage.
Over the past 20 years, there has been an increased interest in
the health benefits and therapeutic potential of omega-3 poly-
unsaturated fatty acids (ω-3 PUFAs) in neurodegeneration
and neuroinflammation due to their anti-oxidant, anti-inflam-
matory, anti-apoptotic, and neuroprotective properties [14,
15], making them safe and very strong candidates for rapid
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Fig. 4 RvD1 down-regulates the expression of pro-inflammatory
markers regulating specific microRNAs. a, b qRT-PCR of selected
microRNAs. *P < 0.05 vs HCb by one-way ANOVA followed by
Bonferroni’s post hoc test. c, d qRT-PCR of the chosen target genes
(via bioinformatics tools) of the selected microRNAs (broken lines
represent control values). *P < 0.05 vs HCb by Student’s t test. Results
are mean ± SEM for N = 6–8 rats
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translation to the clinic [25, 26]. Interestingly, it seems that
only DHA but not EPA exerts neuroprotective and anti-
inflammatory effects in murine models of SCI [27], suggest-
ing that DHA-derived bioactive metabolites could be respon-
sible for such actions. In this study, we used the HCb model, a
reliable and valid paradigm in which neuronal degeneration
can be investigated remotely from the primary site of injury,
where effects of the primary damage can confound the study
of neuropathological changes such as neuronal apoptotic cell
death and neuroinflammation [5, 8]. Herein, we asked if after
brain damage, an alteration of the pro-resolution program me-
diated by specific SPMs might occur in remote regions and its
possible role on remote damage and on functional recovery.
Our data reporting reduced CSF levels of RvD1, and to a
lesser extent of RvD2, coupled with an increased expression
of ALX/FPR2 receptor, demonstrating for the first time that
injured animals undergo a profound reorganization of the
Bpro-resolving system^ in terms of endogenous lipid medi-
ators and their molecular targets. Of note, the up-regulation
of ALX/FPR2 in the Pn was exclusively on astrocytes while
neuronal and microglial cells seemed to lack this receptor as
shown in the immunohistochemistry data. This observation
extends previous findings on the increased levels of glial
ALX/FPR2 in the injured brain of Alzheimer’s disease pa-
tients [28], where it seems that this glial receptor is involved
in amyloid-β internalization [29]. Furthermore, in the study
of Wang and colleagues, the presence of ALX/FPR2 was
also observed in pyramidal neurons in different regions of
the hippocampus, with a particular role in promoting migra-
tion and differentiation of neural stem cells in both rats and
mice [30, 31]. Our lack of detection of this receptor on
axotomized neuronal cells and on microglia suggests that
the heterogeneity in the pathophysiology, the type of neu-
ronal population affected, and the species considered may
account for the observed differences. Furthermore, its
marked expression on astrocytes also suggests that these
cells could indirectly mediate the observed RvD1-induced
neuroprotective effects. Indeed, astrocytes are the most
abundant cell types in the whole CNS and regulate almost
every physiological aspect of the brain, from nutritional and
neuro-signaling support, synaptic plasticity, and constitu-
tion of the blood brain barrier [32] to also immune regula-
tion through astrocyte-microglia cross talk [33].
The alteration of the pro-resolving system observed in our
model led us to assume that in vivo administration of RvD1
could resolve some neuropathological hallmarks occurring in
remote brain areas after injury and on functional recovery.
Indeed, not only systemic RvD1 treatment of injured animals
attenuated neuronal cell death and promoted functional recov-
ery, with animals showing a significantly higher neuronal sur-
vival and neurological recovery, but also strongly reduced
gliosis, with astrocytes and microglial cells being less abun-
dant compared to injured brains. This is in line with recent
evidence that several SPMs, including RvD1, are indeed neu-
roprotective and improve neuronal survival in vitro [34].
Moreover, we also observed that the treatment with RvD1
somehow significantly affected microglia morphology, reduc-
ing the HCb-induced transition into more ramified and thick
processes. Although still controversial, microglia are dynamic
cells whose morphological changes, which occur at different
developmental stages, seem to be associated with their func-
tional activities [35]. In particular, ramified microglia act as
surveying cells by actively sensing the surrounding environ-
ment via dynamic processes, whereas hyper-ramified microg-
lia are characterized by increasing branching processes and
the secretion of pro-inflammatory mediators. Bushy morphol-
ogy represents intermediate microglial activation and amoe-
boid or Bphagocytic^ microglia are highly motile with few
processes and participate in phagocytosis or in inflammatory
functions [35, 36]. Although the exact relationship between
morphological changes and production of either pro- or anti-
inflammatory mediators is poorly understood, our results sug-
gest that RvD1 reduces the overall ramification of microglia,
presumably making themmore prone to migrate and get ready
to activate pro-resolving programs. Accordingly, RvD1 and
RvE1 (an EPA-derived SPM) have been reported to inhibit
microgliosis and pro-inflammatory cytokine release in prima-
ry microglial cultures [37, 38], with the former involving a
mechanism that required regulation of miRNA expression
[38] and promotion of IL-4-induced and alternatively activat-
ed microglia [39]. On the contrary, another DHA-derived
SPM termed neuroprotectin D1 (NPD1) was shown to induce
a ramified microglial phenotype in the choroid layer of the eye
[40], yet NPD1 reduced microglia recruitment and the rami-
fied microglia were non-injuring and resting, not only corrob-
orating the evidence that DHA-derived SPMs are indeed neu-
roprotective but also suggesting that the mechanism of neuro-
protection can entail different microglial morphologies. It is
important to add that since Iba-1 can also stain macrophages
migrated from the periphery, our data also suggest that this
lipid can also impact on recruitment and activation of infiltrat-
ed monocytes/macrophages, which are also involved in brain
neuroinflammation [41]. However, these effects of RvD1 on
microglia are not direct but could rather be mediated by solu-
ble factors released by astrocytes. RvD1 also shortens the
interval of spontaneous recovery of neurological functions,
and this is in line with the whole literature on SPMs, whose
main role is probably that of quantitatively shortening resolu-
tion indices that take into account the temporal activation of
resolution programs. Moreover, although establishing a link
between sparing of neuronal death in a selected brain area and
improvements in functional recovery is always risky, we can-
not exclude that systemic RvD1 treatment might influence
outcomes by acting directly on neurons or on brain centers
and intracellular signaling pathways that differ from those that
we have investigated.
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To date, mechanisms through which resolution of inflam-
mation is achieved are of considerable interest. Along this
line, microRNAs act as posttranscriptional or translational re-
pressors of numerous genes [42], including several genes in-
volved in the overall regulation of immunity and
inflammation [43, 44]. Our data identified a novel resolution
circuit where RvD1 activates its receptor ALX/FPR2 to spe-
cifically regulate miR-219a-1-3p and miR-146b and their
downstream targets TLR4 and IL6R, and to a lesser extent
NF-kB and CD200. These results are consistent with other
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studies in mice and humans, where RvD1 down-regulated the
microRNA-regulated expression of NF-kB and its down-
stream pro-inflammatory cytokines. These microRNAs, to-
gether with others such as miR-21 and miR-208a, and in turn
their target genes, seem to belong to a complex network of
regulatory molecules that promote resolution of acute inflam-
mation [23]. The failure of RvD1 to significantly modulate
miR-21 and miR-208a expression in our model could reflect
differences in either species or brain areas. As for the RvD1/
ALX-regulated microRNA targets, both miR-146b and miR-
219a-1-3p target the TLR4, which is strongly expressed upon
acute and chronic inflammation and whose role is pivotal in
promoting the activation of NF-kB pathway. The observed
RvD1-induced down-regulation of miR-219a-1-3p and miR-
146b-mediated TLR4 not only is in agreement with previous
reports showing that this SPM down-regulates this pathogen-
recognition receptor [45] but also suggests that its pro-
resolving activity is operated by reducing a receptor that is
also involved in binding endogenous molecules produced as
a result of tissue injury [46]. The anti-inflammatory role of
RvD1 in HCb brain injury via its ALX/FPR2-regulated
microRNAs is also explicated by a significant down-
regulation of IL6 receptor, possibly attenuating the inflamma-
tory activity of IL6, which has been recently reported to am-
plify the TLR4 /NF-kB pathway [47]. Overall, it is plausible
that miR-219a-1-3p and miR-146b are both implicated in the
observed neuroprotective and anti-inflammatory effects of
RvD1 by decreasing key pro-inflammatory markers.
In conclusion, our study provides novel evidence for an
alteration of the pro-resolution pathway in remote regions af-
ter focal brain damage, the reinstatement of which by systemic
administration of RvD1 promotes functional recovery and re-
duces neuroinflammation via microRNA-dependent activa-
tion of resolution programs. Failure of activating endogenous
anti-inflammatory and neuroprotective signaling at sites of
secondary injury may be relevant not only for better under-
standing the pathogenesis and the molecular mechanism of
brain injuries but also for the development of selective thera-
pies against these conditions.
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